Daehan Nupharm Co.,Ltd. (KOSDAQ:054670)
South Korea · Delayed Price · Currency is KRW 6,610.00
+60.00 (0.92%)
At close: May 8, 2026
Daehan Nupharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 202,401 | 202,187 | 204,223 | 197,957 | 166,586 |
Other Revenue | - | -0 | - | -0 | -0 |
| 202,401 | 202,187 | 204,223 | 197,957 | 166,586 | |
Revenue Growth (YoY) | 0.11% | -1.00% | 3.16% | 18.83% | 11.58% |
Cost of Revenue | 111,347 | 106,710 | 111,986 | 109,403 | 84,994 |
Gross Profit | 91,054 | 95,477 | 92,236 | 88,554 | 81,593 |
Selling, General & Admin | 69,968 | 70,585 | 63,237 | 56,799 | 50,779 |
Research & Development | 7,499 | 1,329 | 4,106 | 2,284 | 2,156 |
Amortization of Goodwill & Intangibles | 100.14 | 102.28 | 98.91 | 100.22 | 74.06 |
Other Operating Expenses | 836.37 | 1,027 | 4,394 | 744.91 | 680.51 |
Operating Expenses | 79,329 | 76,812 | 73,377 | 60,605 | 55,210 |
Operating Income | 11,725 | 18,665 | 18,859 | 27,949 | 26,383 |
Interest Expense | -1,670 | -1,760 | -1,762 | -1,254 | -907.33 |
Interest & Investment Income | 252.68 | 397.17 | 1,084 | 405.63 | 233.54 |
Earnings From Equity Investments | -253.77 | -466.76 | -142.53 | -26.5 | - |
Currency Exchange Gain (Loss) | 5 | -113.09 | -193.13 | -230.6 | -216.93 |
Other Non Operating Income (Expenses) | 703.77 | 372.02 | 289.66 | 9,275 | -1,347 |
EBT Excluding Unusual Items | 10,762 | 17,094 | 18,136 | 36,119 | 24,145 |
Gain (Loss) on Sale of Investments | 4,511 | 1,281 | 2,547 | -1,608 | -564.19 |
Gain (Loss) on Sale of Assets | -289.84 | -0.53 | -0.53 | 9.51 | -0.36 |
Pretax Income | 14,983 | 18,375 | 20,683 | 34,520 | 23,580 |
Income Tax Expense | -274.54 | 2,907 | 8,141 | 10,203 | 7,886 |
Net Income | 15,258 | 15,468 | 12,542 | 24,317 | 15,694 |
Net Income to Common | 15,258 | 15,468 | 12,542 | 24,317 | 15,694 |
Net Income Growth | -1.36% | 23.33% | -48.42% | 54.95% | - |
Shares Outstanding (Basic) | - | 14 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | - | 14 | 14 | 14 | 14 |
EPS (Basic) | - | 1102.08 | 893.60 | 1732.58 | 1118.17 |
EPS (Diluted) | - | 1102.08 | 893.60 | 1732.58 | 1118.17 |
EPS Growth | - | 23.33% | -48.42% | 54.95% | - |
Free Cash Flow | -45,175 | -14,083 | 2,830 | 10,822 | 5,958 |
Free Cash Flow Per Share | - | -1003.40 | 201.62 | 771.04 | 424.51 |
Gross Margin | 44.99% | 47.22% | 45.16% | 44.73% | 48.98% |
Operating Margin | 5.79% | 9.23% | 9.23% | 14.12% | 15.84% |
Profit Margin | 7.54% | 7.65% | 6.14% | 12.28% | 9.42% |
Free Cash Flow Margin | -22.32% | -6.97% | 1.39% | 5.47% | 3.58% |
EBITDA | 16,027 | 22,763 | 22,340 | 31,177 | 29,712 |
EBITDA Margin | 7.92% | 11.26% | 10.94% | 15.75% | 17.84% |
D&A For EBITDA | 4,302 | 4,098 | 3,481 | 3,228 | 3,330 |
EBIT | 11,725 | 18,665 | 18,859 | 27,949 | 26,383 |
EBIT Margin | 5.79% | 9.23% | 9.23% | 14.12% | 15.84% |
Effective Tax Rate | - | 15.82% | 39.36% | 29.56% | 33.45% |
Advertising Expenses | 2,473 | 3,069 | 3,654 | 3,456 | 4,184 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.